Furthermore, the same group demonstrated that NAFLD/NASH-associated steatohepatitis reduced the ability of immunotherapeutic agents to inhibit intrahepatic transplanted melanoma or colon cancer tumor growth by reducing the number of tumor-infiltrating CD4+T cells. Here, CD4 is linked to metabolic dysfunction-associated steatohepatitis.